Big cash, one bladder cancer bet
- Cretostimogene is the whole story today, with the first FDA filing expected to finish in Q4 2026.
- Cash, cash equivalents, and marketable securities were $1,076.2 million at March 31, 2026.
- The company has no approved product sales yet, so losses and stock sales still fund the plan.
- Biovire adds fill-and-finish revenue and gives CG Oncology more control over part of supply.
- ANI litigation looks less dangerous after a favorable verdict, but appeals can still take time.
A funded race to FDA review
CG Oncology is trying to turn one drug, cretostimogene, into a bladder-sparing treatment for non-muscle invasive bladder cancer. The lead use is high-risk NMIBC in patients who no longer respond to BCG, an older immune treatment used in the bladder. For many of these patients, the next step can be bladder removal surgery, so a working drug would meet a clear medical need.
The company has moved from trial story to filing story. It began its Biologics License Application, or BLA, in Q4 2025 and expects to complete it in Q4 2026. A BLA is the FDA filing used to seek approval for a biologic drug. The latest 10-Q says the plan is still on track.
The balance sheet is the biggest support for the bull case. CG Oncology had $1,076.2 million in cash, cash equivalents, and marketable securities at March 31, 2026. That gives it time to finish the filing, build a launch team, and absorb trial and manufacturing costs without needing near-term product revenue.
The bear case is simple. This is still mainly a one-product company with no approved product sales. If cretostimogene misses at the FDA, launches poorly, runs into supply problems, or loses share to other bladder cancer drugs, there is not much else in the portfolio to protect investors.
No drug sales yet
CG Oncology does not yet make money from selling an approved medicine. Its main business is spending money to develop cretostimogene, seek FDA approval, and prepare for a possible U.S. launch. In Q1 2026, it lost $60.2 million, compared with $34.5 million in Q1 2025.
Small revenue streams exist, but they do not drive the company yet. In Q1 2026, total revenue was $1.083 million. Almost all of that came from commercial and development services after CG Oncology consolidated Biovire, a contract manufacturer that performs fill-and-finish work for drugs and medical devices.
Biovire matters for more than revenue. It gives CG Oncology more control over part of the drug product supply chain for cretostimogene. That helps with a key risk for a company nearing a possible launch, though CG Oncology still relies on other third parties for drug substance and other supply steps.
The funding model is still equity-funded biotech. The company has raised money by selling stock, including net proceeds of $391.4 million from shares sold during Q1 2026 under its Jefferies sales agreement. That cash reduces financing pressure, but it also shows that shareholder dilution is part of the story.
One drug, many bladder cancer tests
Cretostimogene in BOND-003 Cohort C
This is the lead program in high-risk BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 disease. It is the basis for the FDA filing that CG Oncology expects to complete in Q4 2026.
Cretostimogene in BOND-003 Cohort P
This exploratory Phase 3 cohort tests cretostimogene in high-risk BCG-unresponsive NMIBC with only Ta or T1 disease. Positive data could widen use beyond the first planned indication.
PIVOT-006 in intermediate-risk NMIBC
PIVOT-006 is a Phase 3 trial testing cretostimogene after tumor removal in intermediate-risk NMIBC. Enrollment was completed in Q3 2025.
CORE-008 in BCG-naive and BCG-exposed disease
CORE-008 is a Phase 2 program testing cretostimogene in patients who have not had BCG and patients previously exposed to BCG. It also includes a cohort testing cretostimogene with gemcitabine.
CORE-001 with pembrolizumab
CORE-001 tested cretostimogene with pembrolizumab, a checkpoint inhibitor, in high-risk BCG-unresponsive NMIBC. It helps show whether the drug can fit with other cancer therapies.
Biovire fill-and-finish services
Biovire performs contract manufacturing services for other drug and device companies. It also supports part of CG Oncology's own cretostimogene supply needs.
Tiny revenue, two lines
CG Oncology reports one operating segment, but Q1 2026 revenue came from two disclosed lines. The mix is based on the three months ended March 31, 2026: $1.069 million of commercial and development revenue and $14 thousand of license and collaboration revenue.
What can still break
FDA filing or approval setback
High impact · Medium oddsThe BLA for cretostimogene is expected to be completed in Q4 2026. If the FDA refuses to accept the filing, asks for more data, or delays review, the whole investment case slows down. CG Oncology has no approved product sales to soften that hit.
Single-product dependence
High impact · High oddsCretostimogene is the main value driver. Other trials may widen the market, but they still depend on the same drug. A safety issue, weak durability data, or poor doctor adoption would hurt nearly every part of the story.
First commercial launch
High impact · Medium oddsCG Oncology has not launched an approved product before. Even if the FDA approves cretostimogene, the company must build sales, reimbursement, medical education, and distribution. A slow launch could make the large cash balance less valuable than it looks.
Manufacturing handoff risk
Medium impact · Medium oddsBiovire gives CG Oncology more control over fill-and-finish work, which is helpful. It also adds operating complexity. The company still depends on other third parties for drug substance and other supply chain steps, so one weak link could delay supply.
ANI appeal over old rights
Medium impact · Low oddsCG Oncology won a favorable jury verdict in July 2025, and the Q1 2026 filing said post-trial motions were still pending. A later ANI release said it plans to appeal rulings in the case. The risk looks lower than before, but the clean end is still a final appeal outcome or no further challenge.
In one breath
What does CG Oncology do?
CG Oncology is developing cretostimogene, a cancer therapy placed directly into the bladder. The first target is high-risk non-muscle invasive bladder cancer in patients who no longer respond to BCG.
Does CG Oncology have revenue?
It has small revenue from commercial and development services and license collaborations. It does not yet have approved product sales, so the company remains loss-making.
What is the next big event for CGON stock?
The key event is completion of the BLA submission for cretostimogene, expected in Q4 2026. After that, investors will watch whether the FDA accepts the filing for review.
Why did CG Oncology buy or control Biovire?
Biovire gives CG Oncology more control over part of the manufacturing process for cretostimogene. It also adds a small service revenue line from fill-and-finish work for other companies.